Exploring the Potential Use of a PBMC-Based Functional Assay to Identify Predictive Biomarkers for Anti-PD-1 Immunotherapy

The absence of reliable, robust, and non-invasive biomarkers for anti- Programmed cell death protein 1 (PD-1) immunotherapy is an urgent unmet medical need for the treatment of cancer patients. No predictive biomarkers have been established based on the direct assessment of T cell functions, the pri...

Full description

Saved in:

Bibliographic Details
Published in:	International journal of molecular sciences Vol. 21; no. 23; p. 9023
Main Authors:	Bacot, Silvia M., Harper, Taylor A., Matthews, Rebecca L., Fennell, Christie Jane, Akue, Adovi, KuKuruga, Mark A., Lee, Shiowjen, Wang, Tao, Feldman, Gerald M.
Format:	Journal Article
Language:	English
Published:	Switzerland MDPI AG 27.11.2020 MDPI
Subjects:	Antigens, CD - metabolism Biomarkers Biomarkers - metabolism Cancer Cell Proliferation - drug effects Cytokines Cytokines - biosynthesis Cytomegalovirus Deoxyribonucleic acid DNA FDA approval Flow cytometry Granzymes - metabolism Humans Immunoassay Immunotherapy Leukocytes, Mononuclear - metabolism Lymphocyte Activation - drug effects Lymphocytes Mutation Nivolumab - pharmacology Patients Programmed Cell Death 1 Receptor - metabolism T cell receptors T-Lymphocytes, Regulatory - drug effects T-Lymphocytes, Regulatory - immunology Targeted cancer therapy Th1 Cells - immunology Tissue Donors peripheral blood mononuclear cells cytokines T cells biomarker Nivolumab
ISSN:	1422-0067, 1661-6596, 1422-0067
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!